1. Scrip
  2. >>R&D

Simbec-Orion MBO Underpins Build And Buy Strategy

 
• By Mike Ward

Private equity group CBPE Capital acquires majority stake in UK CRO and will finance expansion into US; deal provides Welsh Life Sciences Investment Fund with first exit.

Closed up finger on keyboard with word CLINICAL TRIALS

With backing from private equity group CBPE Capital, Simbec-Orion is on the hunt for assets to increase its US presence. The private equity group, through its £459m CBPE Capital Fund IX, has financed a management buyout at the CRO and is committed to providing further finance for further international growth and expansion by Simbec-Orion. CBPE acquired its majority stake by buying the stake owned by the Welsh Government-backed Welsh Life Sciences Investment Fund.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.

More from R&D